KMDA

Rating neutralTentativeAI MemoPost-earnings T+3

Kamada

As of 2026-05-16/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-16 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

Coverage is limited for this name, so the memo relies on a thinner evidence base.; small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 catch-up from delayed Q1 shipment plus reaffirmed FY26 outlook [#PR-2026-05-13] • 2026-08-13

Expected move: +17%

Biggest risk

The post-print setup is still not a clean upgrade signal. Gross margin fell to 42% from 47%, adjusted EBITDA was flat year over year, and the thesis relies on back-half shipment execution, sales mix improvement, plasma-center ramp and possible business-development delivery rather than a confirmed new transaction or pipeline catalyst.

Invalidation

Break below $6 or thesis failure.

What would change my mind?

Primary-source evidence improved after earnings: Q1 revenue grew 3% to $45.2M, net income rose 4% to $4.1M, the delayed order was delivered in April, and management reaffirmed 2026 guidance while pointing to rising demand for KEDRAB, KAMRAB and VARIZIG, plasma-center ramp potential, biosimilar launches and possible business-development activity [#PR-2026-05-13].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-16

Base target

p=50%

Bull target

$12

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 catch-up from delayed Q1 shipment plus reaffirmed FY26 outlook [#PR-2026-05-13]
San Antonio plasma center commercialization ramp [#PR-2026-05-13]
Business-development or M&A execution using cash position [#PR-2026-05-13]

BearKey bullets

Analyst coverage appears thin, and post-earnings revision data is not available in the packet, lowering confidence in any target-based upside signal.
Gross margin fell to 42% from 47% year over year in Q1 2026, with management attributing the decline to product and market sales mix [#PR-2026-05-13].
Operating expense decline was helped by lower R&D expense following termination of the Phase 3 InnovAATe trial, which reduces pipeline optionality and shifts the story further toward commercial execution [#PR-2026-05-13].

WatchKey bullets

Using the $7.71 anchor price, the packet's $13.00 median analyst target implies roughly 69% upside, but analyst target count is unavailable and coverage is thin.

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $9 (p=50%)

Bull/Bear spread: +53% / -15%

Vs latest close: Bull +53% · Base +17% · Bear -15%

Scenario probabilities

Bull Target: $12 (p=25%)Base Target: $9 (p=50%)Bear Target: $6 (p=25%)

Commentary

T+3 earnings follow-up leaves KMDA in a cautious monitoring bucket rather than a clean post-print upgrade. Primary company disclosures were constructive on guidance, demand and plasma expansion, but the quarter also showed gross-margin compression and shipment timing risk. Immediate analyst revision breadth and consensus surprise data are not available in the packet, so the post-earnings signal remains mixed; the May 15, 2026 anchor close of $7.71 suggests the market had not fully re-rated the story by the end of the week.

As of 2026-05-16 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 catch-up from delayed Q1 shipment plus reaffirmed FY26 outlook [#PR-2026-05-13]
San Antonio plasma center commercialization ramp [#PR-2026-05-13]
Business-development or M&A execution using cash position [#PR-2026-05-13]

Scenarios

Bull Target (Scenario probability)

$12 / p=25% prob

Base Target (Scenario probability)

$9 / p=50% prob

Bear Target (Scenario probability)

$6 / p=25% prob

Price $8 as of 2026-06-02

Nearest Scenario: Bear (∆ 15%)

Targets vs latest close: Bull +53% · Base +17% · Bear -15%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Short-term Catalysts

Next few weeks

Q2 catch-up from delayed Q1 shipment plus reaffirmed FY26 outlook [#PR-2026-05-13]
2026-08-13
Kamada said Q1 2026 revenue was $45.2M, adjusted EBITDA was $11.6M and net income was $4.1M, while Q1 was affected by a temporary delay of a single order that was delivered in April. Management reaffirmed 2026 guidance of $200-$205M revenue and $50-$53M adjusted EBITDA, so the near-term test is whether the deferred shipment and stronger remainder-of-year framing show up cleanly in Q2 results.
Prob 64% • Move 9% • Priced-in 56%

Long-term Catalysts

Months to a year

San Antonio plasma center commercialization ramp [#PR-2026-05-13]
2026-09-30
Kamada said FDA approval of its San Antonio plasma collection center cleared the site to begin commercial sales of normal source plasma, and management described the three Texas plasma centers as a vertical-integration and capacity lever. Investor confidence still depends on evidence that the ramp contributes to revenue and margins over the next several quarters.
Prob 56% • Move 12% • Priced-in 34%
Business-development or M&A execution using cash position [#PR-2026-05-13]
2026-12-31
Management said Kamada continues to evaluate near-term business development and M&A transactions intended to enrich the marketed-products portfolio and generate commercial synergies. The company reported $73.1M of cash, cash equivalents and short-term investments at March 31, 2026, but no specific transaction was announced, so this remains a low-visibility monitoring catalyst rather than a confirmed value driver.
Prob 38% • Move 14% • Priced-in 24%

Risks

Analyst coverage appears thin, and post-earnings revision data is not available in the packet, lowering confidence in any target-based upside signal.
Gross margin fell to 42% from 47% year over year in Q1 2026, with management attributing the decline to product and market sales mix [#PR-2026-05-13].
Operating expense decline was helped by lower R&D expense following termination of the Phase 3 InnovAATe trial, which reduces pipeline optionality and shifts the story further toward commercial execution [#PR-2026-05-13].
Plasma-center ramp, biosimilar launches, MENA distribution expansion, and potential M&A are execution-dependent and may take longer than hoped to translate into visible revenue or margin benefit.
Q1 results were affected by a temporary shipment delay of a single order, highlighting revenue timing lumpiness even if the order was delivered in April [#PR-2026-05-13].

Peers

Symbol	Summary
ASMB	Assembly Biosciences is a small-cap biotech market-cap comp from the packet, but it is development-stage and not a close operating peer to Kamada's commercial plasma-derived portfolio.
FULC	Fulcrum Therapeutics is another size-based biotech comp rather than a direct peer; useful mainly for sentiment and risk-appetite context, not for operating multiple comparison.
ZURA	Zura Bio is a loose small-cap biotech comparator from the packet, but its pipeline profile is not directly comparable to Kamada's marketed-products and plasma-collection model.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-16

AI Stock Memo: KMDA - Kamada - RankAlpha